Recent clinical studies have highlighted significant progress in immunotherapy for hepatocellular carcinoma (HCC). One multicentric investigation across India confirmed the safety and efficacy of the combination regimen atezolizumab plus bevacizumab in unresectable liver cancer, expanding therapeutic options where prior choices were limited. Another phase 2 LIVERTI trial explored dual immune checkpoint blockade targeting TIGIT and PD-1, demonstrating promising antitumor activity potentially overcoming resistance seen with standard immunotherapies. Additionally, combination therapies like transarterial chemoembolization (TACE) paired with targeted tyrosine kinase inhibitors have shown enhanced post-liver transplantation survival, reflecting evolving strategies to improve outcomes in advanced HCC settings.